Quantitative determination of azithromycin in human plasma by liquid chromatography-mass spectrometry and its application in a bioequivalence study

被引:48
作者
Chen, Ben-Mei
Liang, Yi-Zeng [1 ]
Chen, Xiang
Liu, Shao-Gang
Deng, Fu-Liang
Zhou, Ping
机构
[1] Cent S Univ, Res Ctr Modernizat Chinese Med, Coll Chem & Chem Engn, Changsha 410083, Peoples R China
[2] Cent S Univ, Analyt Testing Ctr, Sch Xiangya Med, Changsha 410078, Hunan, Peoples R China
[3] Cent S Univ, Dept Urol, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China
关键词
azithromycin; LC-MS; electrospray ionization; bioequivalence;
D O I
10.1016/j.jpba.2006.05.011
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A sensitive, rapid liquid chromatographic-electrospray ionization mass spectrometric method for determination of azithromycin in human plasma was developed and validated. Azithromycin in plasma (0.2 mL) was extracted with methyl tert-butyl ether-hexane (50:50, v/v), organic phase was transferred to another clear 1.5 mL Eppendorf tube and evaporated to dryness at 40 degrees C and dissolved in mobile phase, samples were separated using a Thermo Hypersil HyPURITY C 18 reversed-phase column (150 mm x 2.1 mm i.d., 5 mu m), together with a mobile phase containing of 20 mM ammonium acetate (pH 5.2)-acetonitrile-methanol (50:40: 10, v/v/v) and was isocratically eluted at a flow rate of 0.2 mL/mm. Azithromycin and its internal standard, clarithromycin, were measured by electrospray ion source in positive selective ion monitoring mode. The method demonstrated that good linearity ranged from 2 to 1000 ng/mL with r = 0.9977. The limit of quantification for azithromycin in plasma was 2 ng/mL with good accuracy and precision. The higher mean extraction recovery, say 81.2% and 75.5% for azithromycin and internal standard (IS), respectively, was obtained in this work. The intra-day and inter-day precision ranged from 4.8% to 8.6% and 6.4% to 10.7% (R.S.D.), respectively. The established method has been successfully applied to bioequivalence study of 2 azithromycin formulations for 24 healthy volunteers. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:480 / 487
页数:8
相关论文
共 30 条
[1]  
ALFREDO PL, 2005, CLIN THER, V27, P1607
[2]   Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers [J].
Amsden, GW ;
Gray, CL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (01) :61-66
[3]   THE EXTRACTION AND QUANTIFICATION OF ERGOSTEROL FROM ECTOMYCORRHIZAL FUNGI AND ROOTS [J].
ANTIBUS, RK ;
SINSABAUGH, RL .
MYCORRHIZA, 1993, 3 (03) :137-144
[4]   High performance liquid chromatographic determination of azithromycin in serum using fluorescence detection and its application in human pharmacokinetic studies [J].
Bahrami, BG ;
Mirzaeei, S ;
Kiani, A .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2005, 820 (02) :277-281
[5]   A new on-line, in-tube pre-column derivatization technique for high performance liquid chromatographic determination of azithromycin in human serum [J].
Bahrami, G ;
Mohammadi, A .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2006, 830 (02) :355-358
[6]   AZITHROMYCIN - THE 1ST AZALIDE ANTIBIOTIC [J].
BALLOW, CH ;
AMSDEN, GW .
ANNALS OF PHARMACOTHERAPY, 1992, 26 (10) :1253-1261
[7]   Validated HPLC-MS-MS method for determination of azithromycin in human plasma [J].
Barrett, B ;
Borek-Dohalsky, V ;
Fejt, P ;
Vaingátová, S ;
Huclová, J ;
Nemec, B ;
Jelínek, I .
ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2005, 383 (02) :210-217
[8]   INVITRO ACTIVITIES OF AZITHROMYCIN (CP-62,993), CLARITHROMYCIN (A-56268-TE-031), ERYTHROMYCIN, ROXITHROMYCIN, AND CLINDAMYCIN [J].
BARRY, AL ;
JONES, RN ;
THORNSBERRY, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (05) :752-754
[9]   Pharmacokinetics of azithromycin in foals after i.v. and oral dose and disposition into phagocytes [J].
Davis, JL ;
Gardner, SY ;
Jones, SL ;
Schwabenton, BA ;
Papich, MG .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2002, 25 (02) :99-104
[10]  
DREW RH, 1992, PHARMACOTHERAPY, V12, P161